Protective effect of intravitreal injection of vasoactive intestinal peptide-loaded liposomes on experimental autoimmune uveoretinitis

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 1, 2009, Pages 9-21

  Camelo, Serge ^a,b,c   Lajavardi, Laure ^a,b,c,d   Bochot, Amélie ^a,d   Goldenberg, Brigitte ^a,b,c   Naud, Marie Christine ^a,b,c   Brunel, Nadège ^e   Lescure, Bernadette ^e   Klein, Christophe ^a,b,c   Fattal, Elias ^a,d   Behar Cohen, Francine ^a,b,c   De Kozak, Yvonne ^a,b,c  

^a INSERM   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CASPASE 3; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; LIPOSOME; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; RANTES; RHODAMINE; TRANSFORMING GROWTH FACTOR BETA2; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE UVEORETINITIS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; IMMUNE RESPONSE; INGUINAL LYMPH NODE; LEWIS RAT; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; RAT; RETINA DETACHMENT; UVEORETINITIS;

ANIMALS; ARRESTIN; AUTOIMMUNE DISEASES; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; INJECTIONS; LIPOSOMES; LYMPH NODES; MACROPHAGES; MALE; RATS; RATS, INBRED LEW; RETINITIS; RHODAMINES; T-LYMPHOCYTES; UVEITIS; VASOACTIVE INTESTINAL PEPTIDE; VITREOUS BODY;

EID: 61749100624     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2008.0074     Document Type: Article

References (61)

1. Yeh, S., Faia, L.J., and Nussenblatt, R.B. Advances in the diagnosis and immunotherapy for ocular inflammatory disease. Semin. Immunopathol. 30:145-164, 2008.
2. Kotter, I., Zierhut, M., Eckstein, A., et al. Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behcet's disease with sight-threatening retinal vasculitis. Adv. Exp. Med. Biol. 528:521-523, 2003.
3. Rosenbaum, J.T., and Smith, J.R. Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin. Exp. Rheumatol. 20:S143-S145, 2002.
4. Murphy, C.C., Greiner, K., Plskova, J., et al. Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch. Ophthalmol. 122:845-851, 2004.
5. Caspi, R.R. Immunotherapy of uveitis: is gene therapy in our future? In: GK., K and Weinreb, R.N., eds. "Essentials in Ophthalmology. Uveitis and Immunological Disorders." New York: Springer; 2007, 193-210
6. Oh-i, K., Keino, H., Goto, H., et al. Intravitreal injection of tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in rats. Br. J. Ophthalmol. 91:237-242, 2007.
7. Nussenblatt, R.B., and Gery, I. Experimental autoimmune uveitis and its relationship to clinical ocular inflammatory disease. J. Autoimmun. 9:575-585, 1996.
8. Nussenblatt, R.B., Dinning, W.J., Fujikawa LS, et al. Local cyclosporine therapy for experimental autoimmune uveitis in rats. Arch. Ophthalmol. 103:1559-1562, 1985.
9. de Kozak, Y., Andrieux, K., Villarroya, H., et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur. J. Immunol. 34:3702-3712, 2004.
10. Smith, J.R., Verwaerde, C., Rolling, F., et al. Tetracycline-inducible viral interleukin-10 intraocular gene transfer, using adeno-associated virus in experimental autoimmune uveoretinitis. Hum. Gene Ther. 16:1037-1046, 2005.
11. Forrester, J.V., and McMenamin, P.G. Immunopathogenic mechanisms in intraocular inflammation. Chem. Immunol. 73:159-185, 1999.
12. Luger, D., and Caspi, R.R. New perspectives on effector mechanisms in uveitis. Semin. Immunopathol. 30:135-143, 2008.
13. de Kozak, Y., Sakai, J., Thillaye, B.. et al. S antigen-induced experimental autoimmune uveo-retinitis in rats. Curr. Eye Res. 1:327-337, 1981.
14. de Kozak Y, Sainte-Laudy J, Benveniste J., and Faure JP. Evidence for immediate hypersensitivity phenomena in experimental autoimmune uveoretinitis. Eur. J. Immunol. 11:612-617, 1981.
15. Forrester, J.V., Huitinga, I., Lumsden, L. et al. Marrow-derived activated macrophages are required during the effector phase of experimental autoimmune uveoretinitis in rats. Curr. Eye Res. 17:426-437, 1998.
16. Xu, H., Forrester, J.V., Liversidge, J., et al. Leukocyte trafficking in experimental autoimmune uveitis: Breakdown of blood-retinal barrier and upregulation of cellular adhesion molecules. Invest. Ophthalmol. Vis. Sci. 44:226-234, 2003.
17. Xu, H., Dawson, R., Crane, I.J., et al. Leukocyte diapedesis in vivo induces transient loss of tight junction protein at the blood-retina barrier. Invest. Ophthalmol. Vis. Sci. 46:2487-2494, 2005.
18. Liversidge, J., Dick, A., and Gordon, S. Nitric oxide mediates apoptosis through formation of peroxynitrite and Fas/Fas-ligand interactions in experimental autoimmune uveitis. Am. J. Pathol. 160:905-916, 2002.
19. de Kozak, Y., and Verwaerde, C. Cytokines in immunotherapy of experimental uveitis. Int. Rev. Immunol. 21:231-253, 2002.
20. Crane I,J., McKillop-Smith, S., Wallace, C.A., et al. Expression of the chemokines MIP-1alpha, MCP-1, and RANTES in experimental autoimmune uveitis. Invest. Ophthalmol. Vis. Sci. 42:1547-1552, 2001.
21. Foxman, E.F., Zhang, M., Hurst, S.D., et al. Inflammatory mediators in uveitis: Differential induction of cytokines and chemokines in Th1- versus Th2-mediated ocular inflammation. J. Immunol. 168:2483-2492, 2002.
22. Crane, I.J., Xu, H., Manivannan, A., et al. Effect of anti macrophage inflammatory protein-1alpha on leukocyte trafficking and disease progression in experimental autoimmune uveoretinitis. Eur. J. Immunol. 33:402-410, 2003.
23. Crane, I.J., Xu, H., Wallace, C., et al. Involvement of CCR5 in the passage of Th1-type cells across the blood-retina barrier in experimental autoimmune uveitis. J. Leukoc. Biol. 79:435-443, 2006.
24. Avichezer, D., Silver, P.B., Chan, C.C., et al. Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype. Invest. Ophthalmol. Vis. Sci. 41:127-131, 2000.
25. Bloquel, C., Bejjani, R., Bigey, P., et al. Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF-alpha soluble receptor in uveitis. FASEB J. 20:389-391, 2006.
26. Said, S.I., and Mutt, V. Polypeptide with broad biological activity: Isolation from small intestine. Science. 169:1217-1218, 1970.
27. Taylor, A.W., Streilein, J.W., and Cousins, S.W. Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor. J. Immunol. 153:1080-1086, 1994.
28. Delgado, M., and Ganea, D. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J. Immunol. 167:966-975, 2001.
29. Delgado, M., Gonzalez-Rey, E., and Ganea, D. Vasoactive intestinal peptide: The dendritic cell -> regulatory T-cell axis. Ann. N. Y. Acad. Sci. 1070:233-238, 2006.
30. Delgado, M., Gonzalez-Rey, E., and Ganea, D. The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J. Immunol. 175:7311-7324, 2005.
31. Gonzalez-Rey, E., Chorny, A., and Delgado, M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat. Rev. Immunol. 7:52-63, 2007.
32. Delgado, M. VIP: A very important peptide in T helper differentiation. Trends Immunol. 24:221-224, 2003.
33. + regulatory T-cells in vivo. J. Leukoc. Biol. 78:1327-1338, 2005.
34. Gonzalez-Rey, E., Chorny, A., Fernandez-Martin, A., et al. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T-cells. Blood. 107:3632-3638, 2006.
35. Keino, H., Kezuka, T., Takeuchi, M., et al. Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide. Arch. Ophthalmol. 122:1179-1184, 2004.
36. Chen, J., Vistica, B., Wiggert, B., et al. The immunomodulator vasoactive intestinal peptide (VIP) does not affect experimental autoimmune uveitis (EAU) in B10.RIII mice. Ocul. Immunol. Inflamm. 13:13-17, 2005.
37. Mody, R., Tramontano, A., and Paul S. Spontaneous hydrolysis of vasoactive intestinal peptide in neutral aqueous solution. Int. J. Pept. Prot. Res. 44:441-447, 1994.
38. Gololobov, G., Noda, Y., Sherman, S., et al. Stabilization of vasoactive intestinal peptide by lipids. J. Pharmacol. Exp. Ther. 285:753-758, 1998.
39. Lajavardi, L., Bochot, A., Camelo, S., et al. Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal peptide encapsulated in liposomes. Invest. Ophthalmol. Vis. Sci. 48:3230-3238, 2007.
40. Ramanathan, S., de Kozak, Y., Saoudi, A., et al. Recombinant IL-4 aggravates experimental autoimmune uveoretinitis in rats. J. Immunol. 157:2209-2215, 1996.
41. Séjourné, F., Rubinstein, I., Suzuki, H., et al. Development of a novel bioactive formulation of vasoactive intestinal peptide in sterically stabilized liposomes. Pharm. Res. 14:362-365, 1997.
42. Verwaerde, C., Naud, M.C., Delanoye, A., et al. Ocular transfer of retinal glial cells transduced ex vivo with adenovirus expressing viral IL-10 or CTLA4-Ig inhibits experimental autoimmune uveoretinitis. Gene Ther. 10:1970-1981, 2003.
43. Camelo, S., Voon, A.S., Bunt, S., et al. Local retention of soluble antigen by potential antigen-presenting cells in the anterior segment of the eye. Invest. Ophthalmol. Vis. Sci. 44:5212-5219, 2003.
44. De Kozak, Y., Omri, B., Smith, J.R., et al. Protein kinase Czeta (PKCzeta) regulates ocular inflammation and apoptosis in endotoxin-induced uveitis (EIU): Signaling molecules involved in EIU resolution by PKCzeta inhibitor and interleukin-13. Am. J. Pathol. 170:1241-1257, 2007.
45. Thillaye-Goldenberg, B., Goureau, O., Naud, M.C., et al. Delayed onset and decreased severity of experimental autoimmune uveoretinitis in mice lacking nitric oxide synthase type 2. J. Neuroimmunol. 110:31-44, 2000.
46. Camelo, S., Lajavardi, L., Bochot, A., et al. Ocular and systemic bio distribution of rhodamine-conjugated liposomes loaded with VIP injected into the vitreous of Lewis rats. Mol. Vis. 13:2263-2274, 2007.
47. Camelo, S., Lajavardi, L., Bochot, A., et al. Drainage of fluorescent liposomes from the vitreous to cervical lymph nodes via conjunctival lymphatics. Ophthalmic Res. 40:145-150, 2008.
48. Qiao, H., Hisatomi, T., Sonoda, K.H., et al. The characterisation of hyalocytes: The origin, phenotype, and turnover. Br. J. Ophthalmol. 89:513-517, 2005.
49. Su, S.B., Grajewski, R.S., Luger, D., et al. Altered chemokine profile associated with exacerbated autoimmune pathology under conditions of genetic interferon-gamma deficiency. Invest. Ophthalmol. Vis. Sci. 48:4616-4625, 2007.
50. Diedrichs-Mohring, M., Nelson, P.J., Proudfoot, A.E., et al. The effect of the CC chemokine receptor antagonist Met-RANTES on experimental autoimmune uveitis and oral tolerance. J. Neuroimmunol. 164:22-30, 2005.
51. Boche, D., Cunningham, C., Gauldie, J., and Perry, V.H. Transforming growth factor-beta 1-mediated neuroprotection against excitotoxic injury in vivo. J. Cereb. Blood Flow Metab. 23:1174-1182, 2003.
52. Xu, H., Silver, P.B., Tarrant, T.K., et al. TGF-beta inhibits activation and uveitogenicity of primary but not of fully polarized retinal antigen-specific memory-effector T-cells. Invest. Ophthalmol. Vis. Sci. 44:4805-4812, 2003.
53. Cortes, L.M., Avichezer, D., Silver, P.B., et al. Inhibitory peptide analogs derived from a major uveitogenic epitope protect from antiretinal autoimmunity by inducing type 2 and regulatory T-cells. J. Leukoc. Biol. 84:577-585, 2008.
54. Mantovani, A., Sozzani, S., Locati, M., et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002; 23:549.
55. Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol. 3:23-35, 2003.
56. Mosser, D.M. The many faces of macrophage activation. J. Leukoc. Biol. 73:209-212, 2003.
57. Caspi, R.R. Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int. Rev. Immunol. 21:197-208, 2002.
58. Hoey, S., Grabowski, P.S., Ralston, S.H., et al. Nitric oxide accelerates the onset and increases the severity of experimental autoimmune uveoretinitis through an IFN-gamma-dependent mechanism. J. Immunol. 159:5132-5142, 1997.
59. Amadi-Obi, A., Yu, C.R., Liu, X., et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat. Med. 13:711-718, 2007.
60. Webster, B., Ekland, E.H., Agle, L.M., et al. Regulation of lymph node vascular growth by dendritic cells. J. Exp. Med. 203:1903-1913, 2006.
61. Delgado, M., Gonzalez-Rey, E., and Ganea, D. VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. FASEB J. 18:1453-1455, 2004.